课题基金 / 基金详情

PHASE I STUDIES OF NEW ANTICANCER AGENTS

PHASE I STUDIES OF NEW ANTICANCER AGENTS
新型抗癌药物的一期研究
批准号：
3610157
负责人：
IRWIN H KRAKOFF
金额：
$1.79万
依托单位：
UNIVERSITY OF TX MD ANDERSON CAN CTR
依托单位国家：
美国
项目类别：
财政年份：
1982
资助国家：
美国
项目状态：
已结题
起止时间：
1982-04-16 至 1985-07-01
来源：
https://reporter.nih.gov/project-details/3610157
关键词：
dosage drug adverse effect drug tolerance

项目摘要

项目成果

IRWIN H KRAKOFF的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The specific objective of this contract will be to provide the Investigational Drug Branch (IDB), CTEP, DCT, NCI, with Phase I clinical evaluations of investigational new drugs which are developed through the DCT Linear Array and are sponsored to the Food and Drug Administration (FDA) under an IND held by DCT. The objective of Phase I studies is to provide the parameters and characteristics of drug toxicity, the maximally tolerated dose, and a recommended Phase II dose.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE II/III CLINICAL TRIALS OF ANTICANCER AGENTS
PHASE II/III CLINICAL TRIALS OF ANTICANCER AGENTS
PHASE II/III CLINICAL TRIALS OF ANTICANCER AGENTS
PHASE II/III CLINICAL TRIALS OF ANTICANCER AGENTS